GlassScriptPhysician profile
Jorge A Prieto
NPI 1942269931
$4,076.41
in general payments reported to CMS, 2019-2025
30 companies · $687 in 2025
The $687 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $736 · 2020: $209 · 2021: $506 · 2022: $751 · 2023: $617 · 2024: $570 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,838 · Education: $36.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,837.91 |
| Education | $36.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,434.04 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $575.62 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $345.62 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $230.94 | 2019-2025 | |
| Celgene Corporation | $191.02 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $155.88 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $146.72 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $114.58 | 2020-2023 | |
| Merck Sharp & Dohme LLC | $87.04 | 2019-2024 | Dificid |
| Ferring Pharmaceuticals INC. | $77.10 | 2019-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $73.76 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $65.55 | 2019-2022 | |
| Madrigal Pharmaceuticals | $64.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Laborie Medical Technologies Corp. | $64.54 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $63.65 | 2024-2025 | Iqirvo, Bylvay |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $59.43 | 2019-2024 | Sucraid |
| Ardelyx, INC. | $51.31 | 2023-2024 | Ibsrela |
| Romark Laboratories, Lc | $42.44 | 2019-2020 | |
| Evoke Pharma, INC. | $28.50 | 2022-2023 | Gimoti |
| Digestive Care, INC. | $26.33 | 2022 | |
| Redhill Biopharma INC. | $26.31 | 2021 | |
| Novo Nordisk INC | $23.36 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $23.21 | 2025 | Zenpep |
| Genzyme Corporation | $19.88 | 2022 | |
| Medline Industries LP | $17.44 | 2024 | |
| Phathom Pharmaceuticals, INC. | $15.95 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $14.01 | 2019 | |
| Shire North American Group INC | $13.23 | 2019 | |
| Allergan, INC. | $12.05 | 2019 | |
| Endo Pharmaceuticals INC. | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Prieto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.